Phaseline

Companies › Sichuan Kelun Pharmaceutical

Sichuan Kelun Pharmaceutical: clinical trials, targets and expected readouts

1 active drug program in 4 registered trials: 1 Phase 1, 1 Phase 4, 1 Phase 3, 1 Phase 2; Psychiatry.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Brexpiprazole
Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist
DRD2, HTR1A, HTR2APhase 1Schizophrenia Disorders; Major Depressive Disorder; Bipolar Depression; Alcohol Use Disorder–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06674694BrexpiprazolePhase 1Schizophrenia DisordersPsychiatryJun 2026
NCT04066192BrexpiprazolePhase 2Alcohol Use DisorderPsychiatryAug 2026
NCT05017311BrexpiprazolePhase 4Major Depressive DisorderPsychiatryDec 2028
NCT04569448BrexpiprazolePhase 3Bipolar DepressionPsychiatrySep 2030

Targets

DRD2 (1) HTR1A (1) HTR2A (1)

Companies with the same targets

Otsuka Vanda Pharmaceuticals Intra-Cellular Therapies Boryung Pharmaceutical Prilenia Changchun GeneScience Pharmaceutical LB Pharmaceuticals Gedeon Richter Jazz Pharmaceuticals Serina Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.